Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M Ridker

Showing results (1-10 of 918) with videos related to

Pageof 92
Sort By:
Circulation|January 5, 2002
On evolutionary biology, inflammation, infection, and the causes of atherosclerosisPaul M Ridker
Clinical Cardiology|April 24, 2003
Connecting the role of C-reactive protein and statins in cardiovascular diseasePaul M Ridker
Lancet (London, England)|January 31, 2012
Coronary artery calcium for guiding statin treatmentPaul M Ridker
The New England Journal of Medicine|June 6, 2019
Methotrexate for Prevention of Cardiovascular Events. ReplyPaul M Ridker
Circulation Research|February 15, 2014
Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debatePaul M Ridker
Circulation|November 12, 2003
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialPaul M Ridker,
Current Atherosclerosis Reports|December 11, 2012
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?Paul M Ridker
Journal of the American College of Cardiology|April 16, 2021
Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and PreventionPaul M Ridker
Clinical Chemistry|January 31, 2009
Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapyPaul M Ridker
Circulation Research|February 1, 2019
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of AtherothrombosisPaul M Ridker
Pageof 92

Showing results (1-10 of 918) with videos related to

Sort By:
Pageof 92
Circulation|January 5, 2002
On evolutionary biology, inflammation, infection, and the causes of atherosclerosisPaul M Ridker
Clinical Cardiology|April 24, 2003
Connecting the role of C-reactive protein and statins in cardiovascular diseasePaul M Ridker
Lancet (London, England)|January 31, 2012
Coronary artery calcium for guiding statin treatmentPaul M Ridker
The New England Journal of Medicine|June 6, 2019
Methotrexate for Prevention of Cardiovascular Events. ReplyPaul M Ridker
Circulation Research|February 15, 2014
Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debatePaul M Ridker
Circulation|November 12, 2003
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialPaul M Ridker,
Current Atherosclerosis Reports|December 11, 2012
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?Paul M Ridker
Journal of the American College of Cardiology|April 16, 2021
Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and PreventionPaul M Ridker
Clinical Chemistry|January 31, 2009
Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapyPaul M Ridker
Circulation Research|February 1, 2019
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of AtherothrombosisPaul M Ridker
Pageof 92